These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 2046808)

  • 1. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 5. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D; Fourtounas C; Tsouchnikas J; Barboutis K
    Am J Kidney Dis; 1996 Jul; 28(1):156. PubMed ID: 8712214
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of recombinant erythropoietin on electrolytes and nutrition in end-stage renal disease patients.
    Kaupke CJ; Vaziri ND
    Int J Artif Organs; 1993 Feb; 16(2):59-62. PubMed ID: 8486413
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 8. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 10. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 12. Human recombinant erythropoietin used to treat a cat with anemia caused by chronic renal failure.
    Henry PA
    Can Vet J; 1994 Jun; 35(6):375. PubMed ID: 8069840
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of uremic anemia and new therapeutic prospectives.
    Lamperi S; Carozzi S; Icardi A; Nasini MG; Traverso GB
    Contrib Nephrol; 1989; 69():190-4; discussion 195-6. PubMed ID: 2661141
    [No Abstract]   [Full Text] [Related]  

  • 16. The end stage renal disease program.
    Goodkin DA
    N Engl J Med; 1993 Jul; 329(2):140; author reply 140-1. PubMed ID: 8510703
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
    Adamson JW; Eschbach JW
    Annu Rev Med; 1990; 41():349-60. PubMed ID: 2184735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin use in pregnancy: two cases and a review of the literature.
    Scott LL; Ramin SM; Richey M; Hanson J; Gilstrap LC
    Am J Perinatol; 1995 Jan; 12(1):22-4. PubMed ID: 7710570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.